Dr. Davar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
Hillman Cancer Center 2ND FLR
Pittsburgh, PA 15232Phone+1 412-623-3398
Summary
- Dr. Diwakar Davar is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including Hillman Cancer Center, UPMC Presbyterian Shadyside - Shadyside, UPMC Magee-Womens Hospital, and UPMC Presbyterian.
He received his medical degree from National University of Singapore and obtained a Masters from the University of Pittsburgh.
He specializes in hematologic oncology and is experienced in melanoma, cSCC, Merkel cell carcinoma and phase I trials.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2013 - 2016- UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
National University of Singapore FOMClass of 2005
Certifications & Licensure
PA State Medical License 2009 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fecal Microbiota Transplant (FMT) in Melanoma Patients Start of enrollment: 2018 Jan 10
- CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Start of enrollment: 2018 Aug 08
- Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab Start of enrollment: 2020 Sep 02
Publications & Presentations
PubMed
- Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced so...Diwakar Davar, Benedito A Carneiro, Grace K Dy, Siddharth Sheth, Mitesh J Borad
Journal for Immunotherapy of Cancer. 2024-11-17 - 2 citationsNeoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
Cancer Cell. 2024-11-11 - Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.William H Hicks, Lauren C Gattie, Mohamad El Shami, Jeffrey I Traylor, Diwakar Davar
Scientific Reports. 2024-10-22
Authored Content
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Join now to see all
Press Mentions
New Drug Combo Shows Significant Promise in Advanced Melanoma TrialNovember 5th, 2024- Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024
- Pitt Study Homes in on Gut Bacteria That Help or Hurt Melanoma TreatmentMarch 21st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
